2025
Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series
Vierra M, Morgan R, Ostowari A, Turaga K, Shergill A, Eng O. Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series. Journal Of Gastrointestinal Oncology 2025, 16: 757-765. PMID: 40386613, PMCID: PMC12078827, DOI: 10.21037/jgo-24-440.Peer-Reviewed Original ResearchLow-grade appendiceal mucinous neoplasmProgression-free survivalSystemic chemotherapyAppendiceal mucinous neoplasmPseudomyxoma peritoneiCase seriesCarcinoembryonic antigenMucinous neoplasmsFolinic acidAnti-vascular endothelial growth factorMedian progression-free survivalCEA responseMetastatic peritoneal diseaseElevated carcinoembryonic antigenPeritoneal cancer indexMedian Follow-UpBenefit of chemotherapyResponse to chemotherapyCycles of chemotherapyOutcomes of patientsTreated 5 patientsUniversity of Chicago Medical CenterEndothelial growth factorUnresectable diseasePeritoneal disease
2020
Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderPlacebo-controlled trialRepetitive behaviorsPharmacological treatmentSpectrum disorderRating ScaleTreatment of RRBsTreatment of autism spectrum disordersEfficacy of pharmacological treatmentsSerotonin reuptake inhibitorsEfficacy of pharmacological agentsPharmacological agentsAntipsychotic medicationReduce RRBsReuptake inhibitorsRRBsStandardized mean differenceEffect sizeRandomized Controlled TrialsDouble-blindOmega-3 fatty acidsFolinic acidStandard study designPrimary outcomeAutism
2015
Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors.
Wang D, Braiteh F, Lee J, Denlinger C, Shepard D, Chaudhary A, Lin Y, Gao L, Asakiewicz C, Nasroulah F, LoRusso P. Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors. Journal Of Clinical Oncology 2015, 33: 691-691. DOI: 10.1200/jco.2015.33.3_suppl.691.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsAdvanced malignant solid tumorsPharmacokinetics of irinotecanMalignant solid tumorsMetabolite SN-38Folinic acidSN-38Safety populationStandard therapyEastern Cooperative Oncology Group performance statusSolid tumorsCycle 1Maximum observed drug concentrationFatigue/astheniaPhase II studyKey eligibility criteriaDose-normalized areaNew safety concernsC maxII studyPerformance statusAdverse eventsStudy treatmentIntravenous infusionPlasma concentrations
2005
Folate supplementation during methotrexate therapy for patients with psoriasis
Strober B, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. Journal Of The American Academy Of Dermatology 2005, 53: 652-659. PMID: 16198787, DOI: 10.1016/j.jaad.2005.06.036.Peer-Reviewed Original ResearchConceptsFolate supplementationSide effectsMethotrexate therapyFolinic acidFolic acidUse of methotrexateEfficacy of methotrexateIncidence of hepatotoxicityTreatment of psoriasisSignificant side effectsUse of folateGastrointestinal intoleranceFolate supplementsInflammatory conditionsMEDLINE searchClinical experiencePatientsMethotrexateFolate antagonistTherapySupplementationSearch termsPsoriasisEfficacyToxicity
1990
Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.
Buckley L, Vacek P, Cooper S. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. The Journal Of Rheumatology 1990, 17: 1158-61. PMID: 2132565.Peer-Reviewed Original ResearchConceptsLow-dose methotrexateFolinic acidDose methotrexateRheumatoid arthritisShort-term side effectsDose of methotrexateIncidence of stomatitisFolinic acid supplementationTerm side effectsLeucovorin treatmentAntiarthritic effectsGastrointestinal toxicityMTX administrationCrossover trialTherapeutic effectAcid supplementationSide effectsMethotrexateLeucovorinArthritisSignificant differencesPatientsAdministrationDosePlacebo
1985
Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil
Danhauser L, Heimer R, Cadman E. Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil. Cancer Chemotherapy And Pharmacology 1985, 15: 214-219. PMID: 3876889, DOI: 10.1007/bf00263888.Peer-Reviewed Original ResearchConceptsSequential methotrexateΜM methotrexateL1210 cellsSynergistic cell killingCultured L1210 cellsFolinic acidMTX pretreatmentMethotrexateL1210 cell growthAcid-precipitable materialHuman neoplasmsPresence of methotrexateFUraInhibitory effectElevated levelsEnhanced cytotoxicityCell killingCell fractionCytotoxicityDUrd incorporationInhibitionThymidylate synthetaseCell growthThymidylate synthesisCultured cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply